LONDON (ShareCast) - (Sharecast News) - AIM-quoted immunotherapies developer Scancell Holdings has been granted a European patent for its Moditope platform by the European Patent Office.
Coming into effect on 13 June, the patent will provide Scancell "broad protection" for its pipeline of Moditope vaccines, including any citrullinated epitopes for the treatment of cancer, including in all major European territories.

Scancell has filed similar patents in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US.

Moditope, a "new class" of potent and selective immunotherapy agents, stimulates the production of killer CD4 T cells which overcomes immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system.

Lindy Durrant, chief scientific officer of Scancell, said, "This is a key patent for Scancell and endorses our work in identifying a new class of cancer vaccine capable of inducing potent immune responses to stress-induced post-translational modifications (siPTM), in this case, through citrullination of cellular proteins."

"We are now well positioned to develop a pipeline of new Moditope therapies with the potential to address the unmet need across a broad range of hard to treat cancers including ovarian, triple negative breast cancer and sarcoma," Durrant added.

As of 1020 BST, Scancell shares had collected 2.41% to 14.85p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE